New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial

Abstract

The development of new-onset diabetes is frequent during the follow-up of treated hypertensive patients. The prevalence of such an event seems to differ depending on the type of antihypertensive therapy used to control blood pressure. Diuretics and -blockers and their association are particularly harmful in this regard. On the contrary, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, alone or in association with diuretics, are associated with a lower prevalence of this metabolic complication. These statements are confirmed by data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study. Longterm studies are required to determine the relevance of development of new-onset diabetes in treated hypertensive patients.

Keywords

new-onset diabetes arterial hypertension antihypertensive therapy diuretics angiotensin receptor blockers

Get full access to this article

View all access options for this article.

References

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.

Kaplan NM The meaning of ALLHAT. J Hypertens 2003; 21:233-4.

Murphy MB , Lewis PJ , Kohner E. , Schumer B. , Dollery CT Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982;2:1293-5.

Lithell H. Hyperinsulinemia, insulin resistance, and the treatment of hypertension . Am J Hypertens 1996;9:150S-154S.

Zanchetti A. , Ruilope LM

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

J Hypertens 2002; 20:2099-110.

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003.

Alderman MH , Cohen H. , Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999;33:1130-4.

Shimamoto M. , Shiiki M. , Ise T. et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 1994;8:755-9.

Savage PJ , Pressel SL , Curb JD et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension:The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:741-51.

10.

Lindholm LH , Ibsen H. , Borch-Johnsen K. et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. JHypertens 2002;20:1879-86.

11.

Sharma AM , Janke J. , Gorzelniak K. , Engeli S. , Luft FC Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609-11.

12.

Thorand B. , Lowel H. , Schneider A. et al. C-reactive protein as a predictor for incident diabetes mellitus among middleaged men: Results from the MONICA augsburg cohort study, 1984-1998 . Arch Intern Med 2003;163:93-9.

13.

Pradhan AD , Manson JE , Rifai N. , Buring JE , Ridker PM Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus . JAMA 2001;286:327-34.

14.

The Diabetes Prevention Research Group. Reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. N Engl J Med 2002;346:393-403.

15.

Teutsch S.

The cost of preventing diabetes: What do we know and what do we need to know?

Diabetes Care 2003; 26:238-9.

16.

Gress TW , Nieto FJ , Shahar E. , Wofford MR , Brancati FL Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.

17.

Chiasson JL , Josse RG , Gomis R. , Hanefeld M. , Karasik A. , Laakso M. Acarbose for prevention of type 2 diabetes mellitas: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.

18.

Raji A. , Seely EW , Bekins SA , Williams GH , Simonson DC Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.Diabetes Care 2003 ;26:172-8.